Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 7.36 USD -0.27%
Market Cap: 2.2B USD
Have any thoughts about
Iovance Biotherapeutics Inc?
Write Note

Iovance Biotherapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Iovance Biotherapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Revenue
$90.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

Iovance Biotherapeutics Inc
Revenue Breakdown

Breakdown by Geography
Iovance Biotherapeutics Inc

Total Revenue: 1.2m USD
100%
Non-Us: 1.2m USD
100.9%

Breakdown by Segments
Iovance Biotherapeutics Inc

Not Available

Iovance Biotherapeutics Inc
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

Iovance Biotherapeutics Inc. is navigating the intricate world of biotechnology with a bold mission: to develop innovative cancer immunotherapies that harness the power of the human immune system. Founded with the vision of transforming how cancer is treated, the company has journeyed through the challenging landscapes of medical research and regulatory scrutiny to bring forth groundbreaking treatments. At the heart of Iovance's strategy is its pioneering work in Tumor-Infiltrating Lymphocyte (TIL) therapy, a process that involves extracting, expanding, and then reinfusing a patient’s own immune cells to target and destroy cancerous tumors. This approach is not only novel but distinctly personal, as it effectively turns the patient's immune system into a bespoke tool against their cancer. The company's business model is centered around the successful clinical development and commercialization of these TIL therapies. As it advances its lead product candidates through critical phase trials, Iovance aims to secure FDA approval, which would transition these therapies from promising research to viable medical treatments. The financial backbone of Iovance comes from its ability to attract investors and establish partnerships, which fund the expensive and time-consuming research and development phase. Its revenue-generating potential will largely depend on the approval and subsequent adoption of its therapies, positioning it within the broader oncology treatment market, which is both highly competitive and highly lucrative. In this demanding arena, Iovance finds itself competing not just on the efficacy of treatments, but also on its capacity to scale production and navigate the complexities of healthcare pricing and reimbursement.

IOVA Intrinsic Value
6.73 USD
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Iovance Biotherapeutics Inc's Revenue?
Revenue
90.9m USD

Based on the financial report for Sep 30, 2024, Iovance Biotherapeutics Inc's Revenue amounts to 90.9m USD.

What is Iovance Biotherapeutics Inc's Revenue growth rate?
Revenue CAGR 1Y
12 697%

Over the last year, the Revenue growth was 12 697%.

Back to Top